Autosomal dominant spastic paraplegia type 6 (Q100874): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
Paraplegia espástica autossômica dominante que geralmente se apresenta no final da adolescência ou início da idade adulta como um fenótipo puro de espasticidade de membros inferiores com hiperreflexia e respostas extensoras plantares, bem como distúrbios leves da bexiga e pés cavos. Raramente, pode apresentar-se como um fenótipo complexo com manifestações adicionais, incluindo epilepsia, neuropatia periférica variável e/ou comprometimento da memória.
description / endescription / en
 
Autosomal dominant spastic paraplegia that usually presents in late adolescence or early adulthood as a pure phenotype of lower limb spasticity with hyperreflexia and extensor plantar responses, as well as mild bladder disturbances and pes cavus. Rarely, it can present as a complex phenotype with additional manifestations including epilepsy, variable peripheral neuropathy and/or memory impairment.

Revision as of 17:39, 16 August 2026

Autosomal dominant spastic paraplegia that usually presents in late adolescence or early adulthood as a pure phenotype of lower limb spasticity with hyperreflexia and extensor plantar responses, as well as mild bladder disturbances and pes cavus. Rarely, it can present as a complex phenotype with additional manifestations including epilepsy, variable peripheral neuropathy and/or memory impairment.
Language Label Description Also known as
default for all languages
ID_434114972
    English
    Autosomal dominant spastic paraplegia type 6
    Autosomal dominant spastic paraplegia that usually presents in late adolescence or early adulthood as a pure phenotype of lower limb spasticity with hyperreflexia and extensor plantar responses, as well as mild bladder disturbances and pes cavus. Rarely, it can present as a complex phenotype with additional manifestations including epilepsy, variable peripheral neuropathy and/or memory impairment.

      Statements